Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S. Topp, Hagop M. Kantarjian, Gary J. Schiller et al.|The Lancet Oncology|2014Cited by 1.3k
CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances<i>In vivo</i>Persistence and Antitumor Efficacy of Adoptively Transferred T CellsClaudia Kowolik, Laurence J.N. Cooper, Max S. Topp et al.|Cancer Research|2006Cited by 487
Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantationTobias Feuchtinger, Hermann Einsele, Kathrin Opherk et al.|Blood|2010Cited by 430
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S. Topp, Jennifer L. Crombie, Matthew J. Matasar et al.|Blood|2024Cited by 28
Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 StudyJennifer L. Crombie, Steve M Ansell, Matthew J. Matasar et al.|Blood|2023Cited by 8